Avalyn Pharma applied for an IPO after completing an oversubscribed financing of $100 million.

The Boston-based biotech company Avalyn Pharma has submitted an initial public offering (IPO) application to the United States and is moving towards the public market. The company focuses on developing inhaled therapies for the treatment of pulmonary fibrosis, a disease with a median survival of only three to five years. Avalyn's IPO is supported by Novo Holdings, which holds approximately 13% of the shares before the offering, indicating to some extent the institution's confidence in its R & D direction. Investors may view this IPO as an early opportunity in an area where treatment innovation remains limited, but the final outcome may depend on clinical progress and execution. (Sina Finance)